16 April 2024
B.P. Marsh & Partners Plc
("B.P. Marsh", the "Company" or the "Group")
Investee Company Update - Completion of disposal by LEBC Holdings Limited of Aspira Corporate Solutions Limited
B.P. Marsh & Partners Plc (AIM:BPM), the specialist private equity investor in early stage financial services businesses, is pleased to announce that, further to the Company's announcement on 13 November 2023, LEBC Holdings Limited ("LEBC") has completed the sale of 100% of Aspira Corporate Solutions Limited, a wholly-owned subsidiary of LEBC, to Titan Wealth Holdings Limited, the discretionary fund management/wealth and asset management business. Completion follows receipt of regulatory approval.
The Group received full repayment of its £3.3m loans to LEBC immediately after completion. As previously stated, LEBC will receive proceeds of sale over a three year earn-out period. The Group expects to receive at least £15,947,000 in line with the Company's most recent published valuation of LEBC as at 31 July 2023.
For further information:
B.P. Marsh & Partners Plc | |
Brian Marsh OBE | +44 (0)20 7233 3112 |
| |
Nominated Adviser & Broker Panmure Gordon |
|
Atholl Tweedie / Amrit Mahbubani / Ailsa MacMaster | +44 (0)20 7886 2500 |
| |
Financial PR & Investor Relations | |
Tavistock | bpmarsh@tavistock.co.uk |
Simon Hudson / Tim Pearson / Katie Hopkins | +44 (0)20 7920 3150 |
Notes to Editors:
B.P. Marsh's current portfolio contains fifteen companies. More detailed descriptions of the portfolio can be found at www.bpmarsh.co.uk.
Since formation over 30 years ago, the Company has assembled a management team with considerable experience both in the financial services sector and in managing private equity investments. Many of the directors have worked with each other in previous roles, and all have worked with each other for over ten years.
- Ends -
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.